Pentoxifylline attenuates proteinuria in anti-Thy1 glomerulonephritis via downregulation of nuclear factor-κB and Smad2/3 signaling

Molecular Medicine

Volumn 21, Issue , 2015, Pages 276-284

  Chen, Yung Ming ^a   Chiang, Wen Chih ^a   Yang, Yalin ^a   Lai, Chun Fu ^a   Wu, Kwan Dun ^a   Lin, Shuei Liong ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ACTIVIN; ACTIVIN A; ALPHA SMOOTH MUSCLE ACTIN; CD2 ASSOCIATED PROTEIN; GLIPICAN 1; I KAPPA B KINASE INHIBITOR; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY THY1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; PENTOXIFYLLINE; PLACEBO; PODOCIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SYNAPTOPODIN; SYNDECAN 4; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WT1 PROTEIN; ANAPLASTIC LYMPHOMA KINASE; CYTOKINE; PROTEIN TYROSINE KINASE; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ELECTRON MICROSCOPY; GENE EXPRESSION REGULATION; GLOMERULUS; GLOMERULUS FILTRATION; HISTOPATHOLOGY; MALE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RAT MODEL; RNA GENE; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; ULTRASTRUCTURE; URINALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; GENE EXPRESSION; GENETICS; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, THY-1; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLOMERULONEPHRITIS; HUMANS; MALE; NF-KAPPA B; PENTOXIFYLLINE; PROTEINURIA; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN;

EID: 84937553551     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00023     Document Type: Article

References (48)

1. Keane W. (2000) Proteinuria: its clinical importance and role in progressive renal disease. Am. J. Kidney Dis. 35:S97-105.
2. Iseki K, Ikemiya Y, Iseki C, Takishita S. (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 63:1468-74.
3. Tryggvason K, Patrakka J, Wartiovaara J. (2006) Hereditary proteinuria syndromes and mechanisms of proteinuria. N. Engl. J. Med. 354:1387-401.
4. Holthofer H. (2007) Molecular architecture of the glomerular slit diaphragm: lessons learnt for a better understanding of disease pathogenesis. Nephrol. Dial. Transplant. 22:2124-8.
5. Haraldsson B, Nyström J, Deen WM. (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev. 88:451-87.
6. Shankland SL. (2006) The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 69:2131-47.
7. Simic I, Tabatabaeifar M, Schaefer F. (2013) Animal models of nephrotic syndrome. Pediatr. Nephrol. 28:2079-88.
8. Chen YM, et al. (1999) Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 56:932-43.
9. Reiser J, et al. (2004) Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J. Biol. Chem. 279:34827-32.
10. Burt D, et al. (2007) The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am. J. Pathol. 171:1789-99.
11. Li Y, et al. (2008) Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am. J. Pathol. 172:299-308.
12. Petersen M, et al. (2008) Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73:705-15.
13. Lee EY, et al. (2009) The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGFbeta, increases podocyte motility and albumin permeability. Am. J. Physiol. Renal Physiol. 297:F85-94.
14. Lai KN, et al. (2009) Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol. Dial. Transplant. 24:62-72.
15. Zhu L, et al. (2013) Synergistic effect of mesangial cell-induced CXCL1 and TGF-β1 in promoting podocyte loss in IgA nephropathy. PLoS One. 8:e73425.
16. Schlöndorff D, Banas B. (2009) The mesangial cell revisited: no cell is an island. J. Am. Soc. Nephrol. 20:1179-87.
17. Menon MC, Chuang PY, He CJ. (2012) The glomerular filtration barrier: components and crosstalk. Int. J. Nephrol. 2012:749010.
18. Haraldsson BS. (2014) The endothelium as part of the integrative glomerular barrier complex. Kidney Int. 85:8-11.
19. Ducloux D, Bresson-Vautrin C, Chalopin JM. (2001) Use of pentoxifylline in membranous nephropathy. Lancet. 357:1672-3.
20. Navarro JF, Mora C, Muros M, Garca J. (2005) Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J. Am. Soc. Nephrol. 16:2119-26.
21. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. (2006) Pentoxifylline ameliorates proteinuria via suppression of renal monocyte chemoattractant protein-1 in subnephrotic primary glomerular diseases. Kidney Int. 69:1410-5.
22. Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. (2008) Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am. J. Kidney Dis. 52:464-74.
23. Renke M, et al. (2010) Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease: placebo controlled, randomized, cross-over study. Acta. Biochim. Pol. 57:119-23.
24. Navarro-González JF, et al. (2015) Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J. Am. Soc. Nephrol. 26:220-9.
25. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. (2010) Animal research: reporting in vivo experiments: ARRIVE guidelines. PLoS Biol. 8:e1000412.
26. Miyauchi M, et al. (2009) Hypertrophy and loss of podocytes in diabetic nephropathy. Intern. Med. 48:1615-20.
27. Chen YM et al. (2004) Dual regulation of tumor necrosis factor-〈-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-κB and activator protein-1: modulation by type III phosphodiesterase inhibition. J. Pharmacol. Exp. Ther. 309:978-86.
28. Lin SL, et al. (2005) Pentoxifylline attenuates tubulointerstitial fibrosis by blocking smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J. Am. Soc. Nephrol. 16:2702-13.
29. Yu D, et al. (2005) Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J. Am. Soc. Nephrol. 16:1733-41.
30. Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW. (1986) Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies: a sequential histological and ultrastructural study in the rat. Lab. Invest. 55:680-7.
31. Schaefer L, et al. (2004) Nephrin expression is increased in anti-Thy1.1-induced glomerulonephritis in rats. Biochem. Biophys. Res. Commun. 324:247-54.
32. Schiffer M, et al. (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Invest. 108:807-16.
33. Ghayur A, et al. (2012) Adenovirus-mediated gene transfer of TGF-β1 to the renal glomeruli leads to proteinuria. Am. J. Pathol. 180:940-51.
34. Yamashita S, Maeshima A, Kojima I, Nojima Y. (2004) Activin A is a potent activator of renal interstitial fibroblasts. J. Am. Soc. Nephrol. 15:91-101.
35. Gaedeke J, Boehler T, Budde K, Neumayer HH, Peters H. (2005) Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. Nephrol. Dial. Transplant. 20:319-28.
36. Fujimoto M, et al. (2009) Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 305:1002-7.
37. Xavier S, et al. (2009) TbetaRI independently activates Smad-and CD2AP-dependent pathways in podocytes. J. Am. Soc. Nephrol. 20:2127-37.
38. Grygielko ET, et al. (2005) Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther. 313:943-51.
39. Sharma K, Jin Y, Guo J, Ziyadeh FN. (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 45:522-30.
40. Border WA, Okuda S, Languino L, Sporn MB, Ruoslahti E. (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature. 346:371-4.
41. Isaka Y, et al. (1996) Gene therapy by skeletal muscle expression of decorin prevent fibrotic disease in rat kidney. Nat. Med. 2:418-23.
42. Kasuga H, et al. (2001) Effects of anti-TGF-β type II receptor antibody on experimental glomerulonephritis. Kidney Int. 60:1745-55.
43. Finer G, et al. (2012) Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. Kidney Int. 82:525-36.
44. Pyke C, Kristensen P, Ostergaard PB, Oturai PS, Rømer J. (1997) Proteoglycan expression in the normal rat kidney. Nephron. 77:461-70.
45. Meuwese MC, et al. (2010) Endothelial surface layer degradation by chronic hyaluronidase infusion induces proteinuria in apolipoprotein E-deficient mice. PLoS One. 5:e14262.
46. Szymczak M, Kuźniar J, Klinger M. (2010) The role of heparanase in diseases of the glomeruli. Arch. Immunol. Ther. Exp. (Warsz). 58:45-56.
47. Gil N, et al. (2012) Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 61:208-16.
48. Sachs N, Sonnenberg A. (2013) Cell-matrix adhesion of podocytes in physiology and disease. Nat. Rev. Nephrol. 9:200-10.